Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Strategies in Biomarker Research
-
1. The proteomic revolution
- Dr. Larry Gold
-
2. Lipid biomarkers: lipidomics of the macrophage and plasma lipidomes
- Prof. Edward A. Dennis
- New Tools for Biomarker Research
-
5. Development of glyco-biomarkers using glycoproteomics technologies
- Dr. Hisashi Narimatsu
-
6. Circulating nucleic acids as biomarkers in cancer patients
- Prof. Klaus Pantel
- Specific Disease Applications
-
7. Biomarkers in breast cancer
- Prof. Joe Duffy
-
8. Bacterial biomarkers
- Dr. Christiane Honisch
-
9. Diabetes biomarkers
- Prof. Naveed Sattar
-
10. Gene networks, brain networks: understanding schizophrenia
- Dr. Daniel Weinberger
-
11. Biomarkers for Huntington's disease - promises and challenges
- Prof. Sarah Tabrizi
-
12. Update on fluid biomarkers for neurodegenerative diseases
- Prof. Henrik Zetterberg
-
13. Biomarkers in osteoarthritis
- Dr. Ali Mobasheri
- Biomarkers in Drug Discovery and Delivery
-
14. Pharmacogenomics: emphasis on clinical drug development
- Dr. Amelia Warner
-
15. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Biomarkers in development, nutrition, and health
-
18. Ethnic differences in nutrition
- Prof. Jose Ordovas
-
19. Non-invasive prenatal diagnostics
- Prof. Y. M. Dennis Lo
-
20. Epigenetic biomarkers in cancer
- Prof. Bob Brown
- Archived Lectures *These may not cover the latest advances in the field
-
21. Biomarkers for Alzheimer's disease
- Prof. Henrik Zetterberg
Printable Handouts
Navigable Slide Index
- Introduction
- George Huntington
- HD characteristics
- The HD mutation and huntingtin protein
- Htt protein
- Cellular pathogenic pathways of Htt
- HD is not just a disease of the basal ganglia
- HD is more than a disease of the brain
- Overview of our HD research at UCL
- Delaying disease onset
- Virtual explosion of HD recent research
- What treatments are on the way
- Novel therapies in or near trials
- Promising preclinical targets in the pipeline
- Understanding the disease in humans
- HD clinical trials: challenges
- Exploring for biomarkers at TRACKHD center
- TRACKHD study design (1)
- TRACKHD study design (2)
- Published results in The Lancet Neurology
- Baseline paper - 2009
- Baseline imaging results
- Baseline cognitive results
- Baseline qMotor and oculomotor results
- 12-months longitudinal analysis - January 2011
- TRACK-HD premanifest A subject
- 12-month imaging change
- 12-month cognitive change (1)
- 12-month cognitive change (2)
- 12-month qMotor change
- Analysis of 24 month observational data
- 24-month change in whole brain atrophy
- 24-month change in caudate volume
- 24-month change in grey matter
- 24-month change in white matter
- Consistent change in early stage HD
- Potential outcome measures for clinical trials
- TRACK-HD 24-month effect sizes
- Track-HD battery sample size estimates
- Atrophy (1)
- Atrophy (2)
- Mutant HTT measured patients' WBCs
- Mutant huntington fragmentation in immune cells
- Mutant HTT in monocytes (1)
- Mutant HTT in monocytes (2)
- Study results - summary
- When does neurodegeneration begin?
- Timescale for brain changes
- Challenges remaining
- Hypotheses to test
- Increased neural activity in premanifest HD
- TrackOnHD - aims
- The premanifest phase of neurodegeneration
- Acknowledgements
- The UCL ION HD team
- Credits
Topics Covered
- Summary of the genetic, pathophysiology and clinical features of Huntington's disease
- Potential drug targets in development for Huntington's disease
- The importance of biomarkers in Huntington's disease
- Current biomarkers in development in Huntington's disease
Talk Citation
Tabrizi, S. (2013, February 28). Biomarkers for Huntington's disease - promises and challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/VLTS6044.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sarah Tabrizi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.